Francesca Molinari
Ente Ospedaliero Cantonale · 86 works · 7,827 citations · h-index 28
Top works
- Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- IDH1mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors
- PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
- Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
- Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer
- Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
- HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
- KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors
- Functions and Regulation of the PTEN Gene in Colorectal Cancer
- APC alterations are frequently involved in the pathogenesis of acinar cell carcinoma of the pancreas, mainly through gene loss and promoter hypermethylation
- Pik3ca, braf, nras and kras mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mcrc) patients treated with egfr-targeting monoclonal antibodies (moabs): results of a european consortium
- Mixed Adenoma Well-differentiated Neuroendocrine Tumor (MANET) of the Digestive System
- Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.
- Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients
- Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma
- EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer.